Revenue Cycle Management in Oncology: Protecting Every Dollar

In Oncology, the financial stakes of revenue cycle management are unlike any other specialty. Drug costs represent 60–80% of practice revenue in the buy-and-bill model , which means a single denied infusion claim — often five or six figures — can wipe out the profit on dozens of routine office visits. Oncology denial rates average approximately 15%, and because the dollar amounts are so high, the financial impact of each denial is exponentially greater than in other specialties.

For independent oncology practices, managing the revenue cycle isn't just a billing function. It's a survival function.

Why Is Oncology Billing So Complex?

Oncology billing complexity stems from the intersection of high-cost drugs, evolving treatment protocols, and intense payer scrutiny:

• Prior authorization for specialty drugs — 30–40% of oncology denials trace to missing or expired authorizations
• J-code unit errors and missing NDC numbers on infusion claims
• Medical necessity documentation connecting diagnosis, treatment history, and clinical guidelines
• Frequent protocol changes as new immunotherapies receive FDA approval
• Buy-and-bill economics where the practice purchases drugs upfront and bills after administration

How Do Oncology Practices Reduce Denial Rates?

Front-end authorization management.

Every infusion treatment should have authorization confirmed — not just submitted, but confirmed — before the drug is administered. Track authorization status in real time and flag expirations before they occur.

Documentation discipline.

For 2026, payers demand documentation that clearly connects diagnosis, response to prior treatment, and clinical guidelines to the selected drug regimen. Generic notes won't suffice.

Coding precision.

J-code accuracy, proper NDC reporting, correct unit calculations, and modifier application must be right on first submission. In oncology, the margin of error is measured in five figures.

TRIARQ Health's Pathways Revenue Performance includes specialty-specific denial prevention built for the unique billing environment of oncology — from infusion authorization tracking to coding validation before claim submission.

What Does AI-Driven Denial Prevention Look Like in Oncology?

AI-driven denial prevention reviews clinical documentation in real time, validates coding against payer-specific requirements, and identifies high-denial-probability claims before submission. Practices using predictive denial tools achieve 30–40% reductions in initial denial rates — denial prevention, not denial management.

When people and intelligence move together, care performs better. Costs fall. Quality rises. Trust grows.